NKGen生物技术公司将在第13届阿尔茨海默病和帕金森病药物开发峰会上展示Troculeucel在治疗神经退行性疾病方面的潜力-动脉网

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit

GlobeNewswire 等信源发布 2025-03-13 08:00



可切换为仅中文







SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y.

加利福尼亚州圣安娜，2025年3月13日（环球新闻社）——NKGen生物技术公司（OTC：NKGN）（“NKGen”或“公司”），一家专注于开发和商业化创新自体及异体自然杀伤（“NK”）细胞疗法的临床阶段生物技术公司，今天宣布，保罗·Y。

Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13.

宋博士，NKGen的董事长兼首席执行官，将出席第13届。

Annual Alzheimer’s & Parkinson’s Drug Development Summit (the “Summit”) to be held in Boston, MA, from March 18–20, 2025. Dr. Song’s presentation will highlight troculeucel, the Company’s autologous, non-genetically modified NK cell therapy, as a potential treatment for neurodegenerative diseases.

2025年3月18日至20日，将在马萨诸塞州波士顿举行年度阿尔茨海默病与帕金森病药物开发峰会（“峰会”）。宋博士的演讲将重点介绍公司自体、非基因修饰的NK细胞疗法troculeucel，作为神经退行性疾病的潜在治疗方案。

The Summit is the only industry-focused event covering the entire drug development process from discovery to commercialization. This year’s Summit will spotlight advancements in neurodegenerative therapeutics, presymptomatic diagnosis, and new targets, modalities, and technologies. Over 150 experts will collaborate to address key challenges and drive the next wave of transformative treatments..

峰会是唯一一个专注于整个药物开发过程的行业活动，涵盖从发现到商业化的全过程。今年的峰会将重点关注神经退行性疾病治疗、症状前诊断以及新靶点、模式和技术的进展。超过150名专家将合作应对关键挑战，推动下一波变革性治疗的发展。

Presentation Details

演示详情

：

Title

标题

：

Showcasing the Potential of Enhanced NK Cell Therapies for the Treatment of Neurodegenerative Disease: Introducing Troculeucel

展示增强型NK细胞疗法治疗神经退行性疾病的潜力：引入Troculeucel

Conference Track:

会议主题：

In Vivo Translation & Early Clinical

体内翻译与早期临床

Date and Time:

日期和时间：

March 20, 2025, at 12:00 PM ET

2025年3月20日，东部时间中午12:00

Dr. Song’s presentation will showcase the potential of enhanced NK cell therapy for the treatment of neurodegenerative disease, introducing troculeucel. Dr. Song will outline the mechanism of troculeucel, the Company’s novel, autologous NK cell therapy, for treating neurodegeneration. He will also present promising data from the Company’s Phase 1 clinical trial, demonstrating early signs of clinical benefit, leading to the U.S.

宋博士的演讲将展示增强型NK细胞疗法在治疗神经退行性疾病方面的潜力，并介绍troculeucel。宋博士将概述该公司新颖的自体NK细胞疗法troculeucel治疗神经退行性疾病的机制。他还将介绍公司1期临床试验的有希望的数据，显示了早期的临床益处迹象，这已引起美国的重视。

Food and Drug Administration Fast Track designation for moderate Alzheimer’s Disease and a new Investigational New Drug for Parkinson’s Disease. Moreover, Dr. Song will highlight the future directions for troculeucel in Frontotemporal Dementia and post-stroke/traumatic brain injury..

食品药品监督管理局对中度阿尔茨海默病的快速通道指定和针对帕金森病的新研究性新药。此外，宋博士还将重点介绍troculeucel在额颞叶痴呆和中风/创伤性脑损伤后的未来发展方向。

Previously disclosed data for troculeucel in Alzheimer’s disease and solid tumors can be found on the Scientific Publications page of the Company’s website at

之前披露的关于阿尔茨海默病和实体瘤的troculeucel数据可在公司网站的科学出版物页面找到。

https://nkgenbiotech.com/scientific-publications/

. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company’s website at

包含troculeucel临床试验更新和监管批准的新闻稿可以在公司网站的新闻页面上找到。

https://nkgenbiotech.com/news/

。

About Troculeucel

关于Troculeucel

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”).

Troculeucel是一种新型的基于细胞的、患者特异性的、体外扩增的自体NK细胞免疫治疗候选药物。NKGen公司正在开发Troculeucel，用于治疗神经退行性疾病和多种癌症。Troculeucel是世界卫生组织（“WHO”）为SNK01指定的国际非专利名称（“INN”）。

The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market..

世界卫生组织国际非专利名称（WHO INN）批准了troculeucel，为SNK01确立了一个全球公认的非专利药物名称，标志着NKGen将这一疗法推向市场的旅程迈出了重要一步。

About NKGen Biotech

关于NKGen生物技术公司

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit

NKGen是一家临床阶段的生物技术公司，专注于开发和商业化创新的自体和异体NK细胞疗法。NKGen总部位于美国加利福尼亚州圣安娜。欲了解更多信息，请访问

www.nkgenbiotech.com

。

Forward-Looking Statements

前瞻性声明

Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿中包含的声明可能包含《证券法》第27A条和修订后的1934年《证券交易法》第21E条所指的“前瞻性陈述”。前瞻性陈述可以通过使用诸如“预期”、“相信”、“可能”、“继续”、“预计”、“估计”、“计划”、“展望”、“未来”和“预测”等词语以及其他类似的表达来识别，这些词语预示或表明未来事件或趋势，或并非历史事实的陈述。

Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates.

由于此类声明受到许多公司无法控制的风险和不确定性的约束，实际结果可能与这些前瞻性声明所表达或暗示的内容存在重大差异。这些声明包括但不限于关于公司开发troculeucel和SNK02的计划及预期时间安排，包括完成其正在进行的临床研究并公布进一步结果的预期时间；以及公司开发其产品候选药物的预期时间安排和其产品候选药物的潜在益处。

Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the .

可能导致前瞻性陈述不确定的风险包括：公司执行其计划和战略的能力；与进行临床研究相关的风险；临床研究的初步和中期结果不一定能预测最终结果的风险，以及随着患者继续入组、数据经过更全面的审查以及更多患者数据的可用性，一个或多个临床结果可能发生重大变化；临床研究的启动、入组、完成以及数据报告可能延迟的风险；研究可能无法按计划完成的风险；。

Internal Contact:

内部联系人：

Denise Chua, MBA, CLS, MLS (ASCP)

丹尼斯·蔡，工商管理硕士，CLS，MLS（ASCP）

SVP, Corporate Affairs

高级副总裁，企业事务部

949-396-6830

dchua@nkgenbiotech.com

External Contacts:

外部联系人：

Chris Calabrese

克里斯·卡拉布雷斯